Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Conditions
Interventions
Adagrasib oral dose of 400 mg twice daily tablets
Pembrolizumab
+2 more
Locations
166
United States
Local Institution - Unk025
Anchorage, Alaska, United States
Local Institution - 017-591
Glendale, Arizona, United States
Local Institution - 017-821
Phoenix, Arizona, United States
Local Institution - Unk047
Anaheim, California, United States
Local Institution - 017-936C
Fountain Valley, California, United States
MemorialCare - Orange Coast Medical Center
Fountain Valley, California, United States
Start Date
November 22, 2022
Primary Completion Date
June 1, 2026
Completion Date
December 1, 2026
Last Updated
August 17, 2025
NCT05098132
NCT06625775
NCT06343402
NCT07171606
NCT06165419
NCT06513663
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain the NCT# and Site #.
CONTACT
Lead Sponsor
Mirati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions